Antibody responses after BNT162b2 vaccination in Japanese geriatric intermediate care facilities
© 2023 The Authors..
Background: To evaluate antibody responses against the primary series of vaccination of severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2] vaccines in the staff and residents of Japanese geriatric intermediate care facilities.
Methods: All subjects (159 staff and 96 residents) received two doses of the BNT162b2 mRNA vaccine 3 weeks apart. Baseline data of subject were collected using a structured form. Serum samples were collected three times: before vaccination, 3 weeks after the first dose, and 4 weeks after the second dose, and anti-receptor binding domain of the spike protein of SARS-CoV-2 [anti-RBD] IgG was measured using two immunoassays.
Results: After the second dose, geometric mean titers [GMT] of anti-RBD with both the Abbott and Roche assay were significantly lower in residents than staff (2282 AU/mL vs. 8505 AU/mL, and 258 U/mL vs. 948 U/mL, respectively). Multivariate analysis of characteristics affecting antibody responses (≥1280 AU/mL for Abbott and > 210 U/mL for Roche) showed lower odds ratios [ORs] for older age (adjusted OR per 10 year increase [aOR] = 0.62, 95 % confidence interval [95 %CI]; 0.38-1.02), steroid usage (aOR = 0.09, 95 %CI; 0.01-0.60) and regular nonsteroidal anti-inflammatory drugs [NSAIDs] usage (aOR = 0.16, 95 %CI; 0.03-0.88).
Conclusions: Elderly people and steroid and NSAID users had lower antibody responses following the second vaccine dose.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Vaccine: X - 15(2023) vom: 12. Dez., Seite 100412 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Suita, Asae [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BNT162b2 |
|---|
| Anmerkungen: |
Date Revised 03.01.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jvacx.2023.100412 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366526278 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366526278 | ||
| 003 | DE-627 | ||
| 005 | 20240108141349.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jvacx.2023.100412 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1247.xml |
| 035 | |a (DE-627)NLM366526278 | ||
| 035 | |a (NLM)38161985 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Suita, Asae |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibody responses after BNT162b2 vaccination in Japanese geriatric intermediate care facilities |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. | ||
| 520 | |a Background: To evaluate antibody responses against the primary series of vaccination of severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2] vaccines in the staff and residents of Japanese geriatric intermediate care facilities | ||
| 520 | |a Methods: All subjects (159 staff and 96 residents) received two doses of the BNT162b2 mRNA vaccine 3 weeks apart. Baseline data of subject were collected using a structured form. Serum samples were collected three times: before vaccination, 3 weeks after the first dose, and 4 weeks after the second dose, and anti-receptor binding domain of the spike protein of SARS-CoV-2 [anti-RBD] IgG was measured using two immunoassays | ||
| 520 | |a Results: After the second dose, geometric mean titers [GMT] of anti-RBD with both the Abbott and Roche assay were significantly lower in residents than staff (2282 AU/mL vs. 8505 AU/mL, and 258 U/mL vs. 948 U/mL, respectively). Multivariate analysis of characteristics affecting antibody responses (≥1280 AU/mL for Abbott and > 210 U/mL for Roche) showed lower odds ratios [ORs] for older age (adjusted OR per 10 year increase [aOR] = 0.62, 95 % confidence interval [95 %CI]; 0.38-1.02), steroid usage (aOR = 0.09, 95 %CI; 0.01-0.60) and regular nonsteroidal anti-inflammatory drugs [NSAIDs] usage (aOR = 0.16, 95 %CI; 0.03-0.88) | ||
| 520 | |a Conclusions: Elderly people and steroid and NSAID users had lower antibody responses following the second vaccine dose | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BNT162b2 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Elderly | |
| 650 | 4 | |a Healthcare worker | |
| 650 | 4 | |a Immunogenicity | |
| 650 | 4 | |a Long-term care facility | |
| 700 | 1 | |a Ohfuji, Satoko |e verfasserin |4 aut | |
| 700 | 1 | |a Kasamatsu, Ayane |e verfasserin |4 aut | |
| 700 | 1 | |a Kondo, Kyoko |e verfasserin |4 aut | |
| 700 | 1 | |a Nakata, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kita, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Deguchi, Akifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Fujimoto, Mikio |e verfasserin |4 aut | |
| 700 | 1 | |a Iba, Kazuko |e verfasserin |4 aut | |
| 700 | 1 | |a Sakamoto, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Iwasaka, Kaori |e verfasserin |4 aut | |
| 700 | 1 | |a Sakamoto, Noboru |e verfasserin |4 aut | |
| 700 | 1 | |a Sakamoto, Hikaru |e verfasserin |4 aut | |
| 700 | 1 | |a Yodoi, Yoshiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kido, Yasutoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Nakagama, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Konishi, Ayako |e verfasserin |4 aut | |
| 700 | 1 | |a Mukai, Emiko |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumoto, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuura, Tomoka |e verfasserin |4 aut | |
| 700 | 1 | |a Kase, Tetsuo |e verfasserin |4 aut | |
| 700 | 1 | |a Kakeya, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Fukushima, Wakaba |e verfasserin |4 aut | |
| 700 | 1 | |a Hirota, Yoshio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine: X |d 2019 |g 15(2023) vom: 12. Dez., Seite 100412 |w (DE-627)NLM299955931 |x 2590-1362 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g day:12 |g month:12 |g pages:100412 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jvacx.2023.100412 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |b 12 |c 12 |h 100412 | ||